Your session is about to expire
← Back to Search
ADAMM- RSM Device for Cystic Fibrosis
N/A
Waitlist Available
Led By Giovanni Ferrara, MD
Research Sponsored by University of Alberta
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial Must have
Be older than 18 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up 6 month duration per participant
Awards & highlights
Study Summary
This trial will test a new device that monitors heart rate, breathing rate, temperature, cough, and activity to see if it can predict worsening or increasing severity of lung conditions.
Eligible Conditions
- Cystic Fibrosis
- Tuberculosis
- Idiopathic Pulmonary Fibrosis
- Lung Transplant
- Bronchiectasis
Timeline
Screening ~ 3 weeks3 visits
Treatment ~ Varies
Follow Up ~ 6 month duration per participant
Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~6 month duration per participant
Treatment Details
Study Objectives
Outcome measures can provide a clearer picture of what you can expect from a treatment.Primary outcome measures
Length of time wearing device (days)
Secondary outcome measures
Prediction of respiratory exacerbations- Number of emergency room visits
Prediction of respiratory exacerbations- Number of hospital admissions
Trial Design
1Treatment groups
Experimental Treatment
Group I: DeviceExperimental Treatment1 Intervention
All participants will wear the device to assist in determining the feasibility of wearing the device.
Treatment
First Studied
Drug Approval Stage
How many patients have taken this drug
ADAMM- RSM Device
2021
N/A
~10
Find a Location
Who is running the clinical trial?
University of AlbertaLead Sponsor
897 Previous Clinical Trials
387,199 Total Patients Enrolled
1 Trials studying Cystic Fibrosis
213 Patients Enrolled for Cystic Fibrosis
Giovanni Ferrara, MDPrincipal InvestigatorUniversity of Alberta
1 Previous Clinical Trials
40 Total Patients Enrolled
Share this study with friends
Copy Link
Messenger